BBA
MRTX

Baker Bros. Advisors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Baker Bros. Advisors’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4,121,440
Closed -$242M – 94
2023
Q4 		$242M Buy
4,121,440
+2,711,656
+192% +$152M 2.76% 6
2023
Q3 		$61.4M Hold
1,409,784
– – 0.35% 21
2023
Q2 		$50.9M Hold
1,409,784
– – 0.29% 23
2023
Q1 		$52.4M Hold
1,409,784
– – 0.29% 21
2022
Q4 		$63.9M Hold
1,409,784
– – 0.38% 20
2022
Q3 		$98.5M Hold
1,409,784
– – 0.64% 14
2022
Q2 		$94.6M Hold
1,409,784
– – 0.54% 13
2022
Q1 		$116M Hold
1,409,784
– – 0.67% 11
2021
Q4 		$207M Hold
1,409,784
– – 1.01% 9
2021
Q3 		$249M Hold
1,409,784
– – 1.1% 11
2021
Q2 		$228M Hold
1,409,784
– – 1% 13
2021
Q1 		$241M Hold
1,409,784
– – 1.05% 14
2020
Q4 		$310M Hold
1,409,784
– – 1.17% 12
2020
Q3 		$234M Hold
1,409,784
– – 0.94% 13
2020
Q2 		$161M Hold
1,409,784
– – 0.71% 15
2020
Q1 		$108M Buy
1,409,784
+102,564
+8% +$9.2M 0.67% 14
2019
Q4 		$168M Hold
1,307,220
– – 0.9% 11
2019
Q3 		$102M Sell
1,307,220
-1,206,242
-48% -$113M 0.69% 15
2019
Q2 		$259M Hold
2,513,462
– – 1.76% 10
2019
Q1 		$184M Hold
2,513,462
– – 1.18% 10
2018
Q4 		$107M Hold
2,513,462
– – 0.87% 13
2018
Q3 		$118M Hold
2,513,462
– – 0.78% 14
2018
Q2 		$124M Sell
2,513,462
-35,999
-1% -$1.36M 0.93% 11
2018
Q1 		$78.3M Hold
2,549,461
– – 0.66% 18
2017
Q4 		$46.5M Buy
2,549,461
+280,263
+12% +$4.35M 0.4% 25
2017
Q3 		$26.5M Hold
2,269,198
– – 0.22% 30
2017
Q2 		$8.28M Hold
2,269,198
– – 0.07% 53
2017
Q1 		$11.8M Hold
2,269,198
– – 0.1% 46
2016
Q4 		$10.8M Hold
2,269,198
– – 0.11% 47
2016
Q3 		$15M Hold
2,269,198
– – 0.14% 43
2016
Q2 		$12.4M Sell
2,269,198
-999,358
-31% -$15.9M 0.13% 48
2016
Q1 		$69.9M Buy
3,268,556
+313,482
+11% +$7.01M 0.74% 19
2015
Q4 		$93.4M Hold
2,955,074
– – 0.77% 20
2015
Q3 		$102M Buy
2,955,074
+150,000
+5% +$4.53M 0.94% 16
2015
Q2 		$88.3M Hold
2,805,074
– – 0.77% 18
2015
Q1 		$82.2M Buy
2,805,074
+425,000
+18% +$9.97M 0.68% 21
2014
Q4 		$44.1M Hold
2,380,074
– – 0.45% 27
2014
Q3 		$41.7M Hold
2,380,074
– – 0.52% 24
2014
Q2 		$47.6M Hold
2,380,074
– – 0.58% 24
2014
Q1 		$45.4M Hold
2,380,074
– – 0.58% 26
2013
Q4 		$39.6M Buy
2,380,074
+400,000
+20% +$6.84M 0.56% 26
2013
Q3 		$30M Buy
+1,980,074
New +$19.5M 0.43% 27

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Baker Bros. Advisors's MRTX Position: Q1 2024 in Review

Baker Bros. Advisors sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 4,121,440 shares — an estimated $242M sold.

Baker Bros. Advisors first reported a position in MRTX in Q3 2013 and held it in 42 quarters. The position peaked at $310M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Baker Bros. Advisors reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Baker Bros. Advisors sold 4,121,440 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $242M.
  • Baker Bros. Advisors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2013 and held it in 42 quarters.
  • Baker Bros. Advisors's Mirati Therapeutics, Inc. Common Stock position peaked at $310M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Baker Bros. Advisors's 13F filing for Q1 2024, filed 15 May 2024.